SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zangari, M. Articles by Tricot, G. Search for Related Content PubMed PubMed Citation Articles by Zangari, M. Articles by Tricot, G. Related Collections Hemostasis, Thrombosis, and Vascular Biology Brief Reports Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2001, Vol. 98, No. 5, pp. 1614-1615 BRIEF REPORT Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Maurizio Zangari, Elias Anaissie, Bart Barlogie, Ashraf Badros, Raman Desikan, A. Viju Gopal, Christopher Morris, Amir Toor, Eric Siegel, Louis Fink, and Guido Tricot From the Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR. The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study. The 2 study arms were comparable with respect to key myeloma prognostic factors and known risk factors for DVT. One hundred patients received induction chemotherapy including 4 cycles of continuous infusion of combinations of dexamethasone, vincristine, doxorubicin, cyclophosphamide, etoposide, and cisplatin, and each patient completed at least one induction cycle. DVT developed in 14 of 50 patients (28%) randomly assigned to receive thalidomide but in only 2 of 50 patients (4%) not given the agent (P = .002). All episodes of DVT occurred during the first 3 cycles of induction. Administration of thalidomide was resumed safely in 75% of patients receiving anticoagulation therapy. Thus, thalidomide given in combination with multiagent chemotherapy and dexamethasone is associated with a significantly increased risk of DVT, which appears to be safely treated with anticoagulation and does not necessarily warrant discontinuation of thalidomide. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Thromboembolic events during treatment with thalidomide Eleonora Urbauer, Hannes Kaufmann, Thomas Nösslinger, Markus Raderer, and Johannes Drach Blood 2002 99: 4247-4248. [Full Text] [PDF] This article has been cited by other articles: A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action J. Clin. Oncol., October 10, 2009; 27(29): 4919 - 4926. [Abstract] [Full Text] [PDF] A. Falanga and M. Marchetti Venous Thromboembolism in the Hematologic Malignancies J. Clin. Oncol., October 10, 2009; 27(29): 4848 - 4857. [Abstract] [Full Text] [PDF] T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF] S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, and O. Landgren Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma Blood, November 1, 2008; 112(9): 3582 - 3586. [Abstract] [Full Text] [PDF] Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF] M. Zangari, J. Guerrero, F. Cavallo, H. K. Prasad, D. Esseltine, and L. Fink Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma Haematologica, June 1, 2008; 93(6): 953 - 954. [Full Text] [PDF] E. N. Brown and J. D. Herrington Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137. [Abstract] [PDF] V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF] C. W. Francis, A. K. Kakkar, M. N. Levine, and G. H. Lyman Prevention of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 250 - 256. [Abstract] [Full Text] [PDF] G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5490 - 5505. [Abstract] [Full Text] [PDF] J. Nishioka and S. Goodin Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 85 - 97. [Abstract] [PDF] L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito Dietary supplements in patients with cancer: Risks and key concepts, part 1 Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 369 - 381. [Abstract] [Full Text] [PDF] C. S. Eby Bleeding and Thrombosis Risks in Plasma Cell Dyscrasias Hematology, January 1, 2007; 2007(1): 158 - 164. [Abstract] [Full Text] [PDF] J. Woodley-Cook, L. Y.Y. Shin, L. Swystun, S. Caruso, S. Beaudin, and P. C. Liaw Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway Mol. Cancer Ther., December 1, 2006; 5(12): 3303 - 3311. [Abstract] [Full Text] [PDF] T. Y. Kang, C. J. Lowe, and M. A. Sekeres Thalidomide Use and Digital Gangrene J. Clin. Oncol., November 20, 2006; 24(33): 5328 - 5328. [Full Text] [PDF] M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in Cancer Patients: Pathogenesis and Treatment Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF] M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF] A. M. Levine, A. Tulpule, D. I. Quinn, G. Gorospe III, D. L. Smith, L. Hornor, W. D. Boswell, B. M. Espina, S. G. Groshen, R. Masood, et al. Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy J. Clin. Oncol., April 10, 2006; 24(11): 1712 - 1719. [Abstract] [Full Text] [PDF] S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436. [Abstract] [Full Text] [PDF] R. Z. Orlowski Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 338 - 347. [Abstract] [Full Text] [PDF] B. M. Augustson, G. Begum, J. A. Dunn, N. J. Barth, F. Davies, G. Morgan, J. Behrens, A. Smith, J. A. Child, and M. T. Drayson Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party J. Clin. Oncol., December 20, 2005; 23(36): 9219 - 9226. [Abstract] [Full Text] [PDF] S. V. Rajkumar and R. A. Kyle Multiple Myeloma: Diagnosis and Treatment Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382. [Abstract] [PDF] G. Saunders Overview of drug therapy for multiple myeloma Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100. [Abstract] [PDF] M. E Gordinier and D. S Dizon Dyspnea During Thalidomide Treatment for Advanced Ovarian Cancer Ann. Pharmacother., May 1, 2005; 39(5): 962 - 965. [Abstract] [Full Text] [PDF] G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood, April 1, 2005; 105(7): 2949 - 2951. [Abstract] [Full Text] [PDF] P. G. Richardson, A. Kassarjian, and W. Jing Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull N. Engl. J. Med., December 16, 2004; 351(25): 2637 - 2645. [Full Text] [PDF] A. K. Stewart, C. I. Chen, K. Howson-Jan, D. White, J. Roy, M. J. Kovacs, C. Shustik, A. Sadura, L. Shepherd, K. Ding, et al. Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant Clin. Cancer Res., December 15, 2004; 10(24): 8170 - 8176. [Abstract] [Full Text] [PDF] H. Hassoun, L. Reich, V. M. Klimek, T. Kewalramani, M. Dhodapkar, L. Drake, R. Zimman, C. V. Hedvat, T.-F. Julie, F. Martin, et al. Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2409 - 2409. [Abstract] R. A. Kyle and S. V. Rajkumar Multiple Myeloma N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873. [Full Text] [PDF] S. Sallah, A. Husain, J. Wan, P. Vos, and N. P. Nguyen The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance Ann. Onc., October 1, 2004; 15(10): 1490 - 1494. [Abstract] [Full Text] [PDF] V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos Thalidomide in cancer medicine Ann. Onc., August 1, 2004; 15(8): 1151 - 1160. [Abstract] [Full Text] [PDF] R. A. Mesa, M. A. Elliott, G. Schroeder, and A. Tefferi Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia Mayo Clin. Proc., July 1, 2004; 79(7): 883 - 889. [Abstract] [PDF] S. V. Rajkumar Thalidomide: Tragic Past and Promising Future Mayo Clin. Proc., July 1, 2004; 79(7): 899 - 903. [PDF] S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF] C Pagnoux, V Lutz-Zarrouk, M Michel, A Schaeffer, and B Godeau Letter to the Editor Lupus, June 1, 2004; 13(6): 481 - 482. [PDF] M. Miceli, R. Atoui, R. Thertulien, B. Barlogie, E. Anaissie, R. Walker, and L. Jones-Jackson Deep Septic Thrombophlebitis: An Unrecognized Cause of Relapsing Bacteremia in Patients With Cancer J. Clin. Oncol., April 15, 2004; 22(8): 1529 - 1531. [Full Text] K. Zervas, M. A. Dimopoulos, E. Hatzicharissi, A. Anagnostopoulos, M. Papaioannou, Ch. Mitsouli, P. Panagiotidis, J. Korantzis, M. Tzilianos, and A. Maniatis Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study Ann. Onc., January 1, 2004; 15(1): 134 - 138. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454. [Abstract] [Full Text] [PDF] S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model Clin. Cancer Res., October 1, 2003; 9(12): 4619 - 4626. [Abstract] [Full Text] [PDF] M. G Tektonidou and P. G Vlachoyiannopoulos Letter to the Editor Lupus, September 1, 2003; 12(9): 723 - 724. [PDF] F. A. Anderson Jr. and F. A. Spencer Risk Factors for Venous Thromboembolism Circulation, June 17, 2003; 107(90231): I-9 - 16. [Abstract] [Full Text] [PDF] A. Y.Y. Lee and M. N. Levine Venous Thromboembolism and Cancer: Risks and Outcomes Circulation, June 17, 2003; 107(90231): I-17 - 21. [Abstract] [Full Text] [PDF] M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF] R. A. Mesa, D. P. Steensma, A. Pardanani, C.-Y. Li, M. Elliott, S. H. Kaufmann, G. Wiseman, L. A. Gray, G. Schroeder, T. Reeder, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood, April 1, 2003; 101(7): 2534 - 2541. [Abstract] [Full Text] [PDF] S. Kumar, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, S. M. Geyer, N. L. Iturria, R. Fonseca, S. R. Hayman, J. A. Lust, R. A. Kyle, et al. Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma Mayo Clin. Proc., January 1, 2003; 78(1): 34 - 39. [Abstract] [PDF] S. V. Rajkumar, S. Hayman, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, P. R. Greipp, S. Geyer, N. Iturria, R. Fonseca, J. A. Lust, et al. Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma J. Clin. Oncol., November 1, 2002; 20(21): 4319 - 4323. [Abstract] [Full Text] [PDF] K. Neben, T. Moehler, A. Benner, A. Kraemer, G. Egerer, A. D. Ho, and H. Goldschmidt Dose-dependent Effect of Thalidomide on Overall Survival in Relapsed Multiple Myeloma Clin. Cancer Res., November 1, 2002; 8(11): 3377 - 3382. [Abstract] [Full Text] [PDF] M. Cavo, E. Zamagni, C. Cellini, P. Tosi, D. Cangini, M. Cini, L. Valdre, G. Palareti, L. Masini, S. Tura, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood, August 28, 2002; 100(6): 2272 - 2272. [Full Text] [PDF] S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G Current Therapy for Multiple Myeloma Mayo Clin. Proc., August 1, 2002; 77(8): 813 - 822. [Abstract] [PDF] M. Zangari, E. Siegel, B. Barlogie, E. Anaissie, F. Saghafifar, A. Fassas, C. Morris, L. Fink, and G. Tricot Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood, July 30, 2002; 100(4): 1168 - 1171. [Abstract] [Full Text] [PDF] V. Kaushal, M. Kohli, M. Zangari, L. Fink, P. Mehta, B. Kuenen, and G. Giaccone Endothelial Dysfunction in Antiangiogenesis-Associated Thrombosis J. Clin. Oncol., July 1, 2002; 20(13): 3042 - 3043. [Full Text] [PDF] B. Escudier, N. Lassau, D. Couanet, E. Angevin, F. Mesrati, S. Leborgne, A. Garofano, C. Leboulaire, N. Dupouy, and A. Laplanche Phase II trial of thalidomide in renal-cell carcinoma Ann. Onc., July 1, 2002; 13(7): 1029 - 1035. [Abstract] [Full Text] [PDF] E. Urbauer, H. Kaufmann, T. Nosslinger, M. Raderer, and J. Drach Thromboembolic events during treatment with thalidomide Blood, May 13, 2002; 99(11): 4247 - 4248. [Full Text] [PDF] F.-C. Lee ; and M. Zangari Second response to lower-dose thalidomide in a patient with multiple myeloma Blood, May 13, 2002; 99(11): 4248 - 4249. [Full Text] [PDF] J-C Piette, A Sbai, and C Frances Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus Lupus, February 1, 2002; 11(2): 67 - 70. [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020